Scheduling of gemcitabine and cisplatin in Lewis Lung tumour bearing mice

European Journal of Cancer

Volumn 35, Issue 5, 1999, Pages 808-814

  Van Moorsel, C J A ^a   Pinedo, H M ^a   Veerman, G ^a   Vermorken, J B ^b   Postmus, P E ^a   Peters, G J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Amifostine; Cisplatin; Gemcitabine; Non small cell lung cancer; Schedule dependence

Indexed keywords

AMIFOSTINE; CISPLATIN; GEMCITABINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT PLANNING; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; LUNG NEOPLASMS; MICE; NEOPLASM TRANSPLANTATION;

EID: 0033036665     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00004-0     Document Type: Article

References (28)

1. Hertel L.W., Kroin J.S., Misner J.W., Tustin J.M. Synthesis of 2′-deoxy-2′,2′-difluoro-D-ribose and 2-Deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J. Org. Chem. 53:1988;2406-2409.
2. Van Moorsel C.J.A., Peters G.J., Pinedo H.M. Gemcitabine: future prospects of single-agents and combination studies. The Oncologist. 2:1997;127-134.
3. Huang P., Chubb S., Hertel L.W., Grindey G.B., Plunkett W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res. 51:1991;6110-6117.
4. Heinemann V., Hertel L.W., Grindey G.B., Plunkett W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res. 48:1988;4024-4031.
5. Ruiz van Haperen V.W.T., Veerman G., Vermorken J.B., Peters G.J. 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem. Pharmacol. 46:1993;762-766.
6. Sundquist W.I., Lippard S.J. The coordination chemistry of platinum anticancer drugs and related compounds with DNA. Coord. Chem. Rev. 100:1990;293-322.
7. Terheggen P.M.A.B., Emondt J.Y., Floot B.G.J., et al. Correlation between cell killing by cisdiamminedichloroplatinum(II) in six mammalian cell lines and binding of a cisdiamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 50:1990;3556-3561.
8. Parker R.J., Gill I., Tarone R., et al. Platinum DNA-damage in leucocyte DNA of patients receiving cisplatin and carboplatin chemotherapy, measured by atomic absorption spectrometry. Carcinogenesis. 12:1991;1253-1258.
9. Schellens J.H.M., Ma J., Planting A.S.Th., et al. Relationship between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Br. J. Cancer. 73:1996;1569-1575.
10. Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin. Cancer Res. 2:1996;521-530.
11. Van Moorsel C.J.A., Veerman G., Bergman A.M., et al. Combination chemotherapy studies with gemcitabine. Semin. Oncol. 24:(Suppl. 7):1997;17-23.
12. Van Moorsel CJA, Pinedo HM, Veerman G, et al. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small cell lung cancer cell lines. Br J Cancer 1999, in press.
13. Braakhuis B.J.M., Ruiz van Haperen V.W.T., Welters M.J.P., Peters G.J. Schedule-dependent therapeutic efficacy of the combination of gemcitabine and cisplatin in head and neck cancer xenografts. Eur. J. Cancer. 31A:1995;2335-2340.
14. Veerman G., Ruiz van Haperen V.W.T., Vermorken J.B., et al. Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difluorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother. Pharmacol. 38:1996;335-342.
15. Peters G.J., Bergman A.M., Ruiz van Haperen V.W.T., Veerman G., Kuiper C.M., Braakhuis B.J.M. Interaction between cisplatin and gemcitabine in vitro and in vivo. Semin. Oncol. 22:(Suppl.):1995;72-79.
16. Tanzer LR, Rutherford PG, Self TD, Seymour PD, Theobald KS, Merriman RL. Antitumor activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6. Proc AACR 1995, 36, abstract 1761.
17. Abratt R.P., Bezwoda W.R., Goedhals L., Hacking D.J. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small cell lung cancer. J. Clin. Oncol. 15:1997;744-749.
18. Crino L., Scagliotto G., Marangolo M., et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cancer: a phase II study. J. Clin. Oncol. 15:1997;297-303.
19. Steward W.P., Dunlop D.J., Dabouis G., Lacroix H., Talbot D. Phase I/II study of gemcitabine and cisplatin in non-small cell lung cancer: preliminary results. Semin. Oncol. 5:(Suppl. 10):1996;143-147.
20. Shepherd FA, Anglin G, Abratt R, et al. Influence of gemcitabine (gem) and cisplatin (cp) schedule on response and survival in advanced non-small cell lung cancer (NSCLC). Proc ASCO 1998, 17, abstract 1817.
21. Abratt R.P., Sandler A., Crino L., et al. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery. Semin. Oncol. 25:(Suppl. 9):1998;35-43.
22. Van der Vijgh W.J.F., Peters G.J. Protection of normal tissues from the cytotoxic effect of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects. Semin. Oncol. 21:1994;2-7.
23. Mayo JG. Biologic characterization of the subcutaneously implanted Lewis Lung tumor. Cancer Chemother Rep 1972, part 2 (3) 1, 325-330.
24. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 24:1989;148-154.
25. UKCCCR Guidelines for the Welfare of Animals in Experimental Neoplasia, 2nd Ed. Br J Cancer 1998, 77 (1).
26. Van der Wilt C.L., Van Laar J.A.M., Gyergyay F., Smid K., Peters G.J. Biochemical modification of the toxicity and antitumour effect of 5-fluorouracil and cisplatinum by WR-2721 in mice. Eur. J. Cancer. 28A:1992;2017-2024.
27. Peters G.J. Therapy related disturbances in nucleotides in cancer cells. Adv. Exp. Med. Biol. 370:1995;95-107.
28. Van Laar J.A.M., Van der Wilt C.L., Treskes M., Van der Vijgh W.J.F., Peters G.J. Effect of WR-2721 on the toxicity and antitumour activity of the combination of carboplatin and 5-fluorouracil. Cancer Chemother. Pharmacol. 31:1992;97-102.